The topics of this focus are broadly diversified and range from pharmacokinetics in special patient populations to the effects of psychoactive substances and pharmaceutical thechnology research. Two research groups are also dedicated to various pharmacological questions in paediatrics.

• Adverse drug reactions and drug safety
• Development of bedside decision support tools to benefit sick children and their caregivers
• Effects of growth, development and diseases on how to optimize the use of medicines in neonates, infants and children
• Examination of the effects of psychoactive substances in humans
• HIV pharmacology with a focus on drug interactions and pharmacokinetics in specialized populations
• Pharmaceutical technology with a focus on drug delivery and drug targeting

Leukocyte Count and Coronary Artery Disease Events in People with HIV: A Longitudinal Study. Avery EF, Kleynhans JN, Ledergerber B, Schoepf IC, Thorball CW, Kootstra NA, Reiss P, Ryom L, Braun DL, Thurnheer MC, Marzolini C, Seneghini M, Bernasconi E, Cavassini M, Buvelot H, Kouyos RD, Fellay J, Günthard HF, Tarr PE; Swiss HIV Cohort Study. Clin Infect Dis. 2023 Jan 23:ciad033. doi: 10.1093/cid/ciad033. Epub ahead of print. PMID: 36688465.

Management of drug-drug interactions between long-acting cabotegravir and rilpivirine and comedications with inducing properties: a modelling study. Bettonte S, Berton M, Stader F, Battegay M, Marzolini C. Clin Infect Dis. 2022 Nov 15:ciac901. doi: 10.1093/cid/ciac901. Epub ahead of print. PMID: 36377436.

Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions. Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, Pozniak A, Boffito M, Waters L, Burger D, Back D, Khoo S. Ann Intern Med. 2022 Mar 1. Epub ahead of print.

Fluvoxamine for the treatment of COVID-19. Lancet Glob Health. Marzolini C, Marra F, Boyle A, Khoo S, Back DJ. Lancet Glob Health. 2022 Mar;10(3):e331.

Coronary Artery Disease-Associated and Longevity-Associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living With Human Immunodeficiency Virus: The Swiss HIV Cohort Study Schoepf IC, Thorball CW, Ledergerber B, Engel T, Raffenberg M, Kootstra NA, Reiss P, Hasse B, Marzolini C, Thurnheer C, Seneghini M, Bernasconi E, Cavassini M, Buvelot H, Kouyos R, Günthard HF, Fellay J, Tarr PE; Swiss HIV Cohort Study. Clin Infect Dis. 2021 Nov 2;73(9):1597-1604.

Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial Bielicki JA, Stöhr W, Barratt S, Dunn D, Naufal N, Roland D, Sturgeon K, Finn A, Rodriguez-Ruiz JP, Malhotra-Kumar S, Powell C, Faust SN, Alcock AE, Hall D, Robinson G, Hawcutt DB, Lyttle MD, Gibb DM, Sharland M; PERUKI, GAPRUKI, and the CAP-IT Trial Group. JAMA. 2021 Nov 2;326(17):1713-1724.

Coronary Artery Disease-associated and Longevity-associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living with HIV: The Swiss HIV Cohort Study. Schoepf IC, Thorball CW, Ledergerber B, Engel T, Raffenberg M, Kootstra NA, Reiss P, Hasse B, Marzolini C, Thurnheer C, Seneghini M, Bernasconi E, Cavassini M, Buvelot H, Kouyos R, Günthard HF, Fellay J, Tarr PE; , for the Swiss HIV Cohort Study. Clin Infect Dis. 2021 Jun 6:ciab521. doi: 10.1093/cid/ciab521. Epub ahead of print. PMID: 34091660.